SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of | January | 2015 | ||
Commission File Number | 001-36458 |
Neovasc Inc. |
(Translation of registrant’s name into English) |
Suite 2135 — 13700 Mayfield Place Richmond, British Columbia, Canada, V6V 2E4 |
(Address of principal executive offices) |
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F | Form 40-F | X |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
DOCUMENTS INCLUDED AS PART OF THIS REPORT
Document | ||
1 | News Release – Neovasc to Ring Closing Bell at Nasdaq | |
This Report on Form 6-K is incorporated by reference into the Registration Statement on Form F-10 of the Registrant, which was originally filed with the Securities and Exchange Commission on April 17, 2014 (File No. 333-195360), and the Registration Statement on Form S-8 of the Registrant, which was originally filed with the Securities and Exchange Commission on June 24, 2014 (File No. 333-196986).
Document 1
Neovasc to Ring Closing Bell at Nasdaq
NASDAQ: NVCN
TSX: NVC
VANCOUVER, Jan. 13, 2015 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced it will visit the Nasdaq MarketSite in Times Square in celebration of its Nasdaq listing. Neovasc is focused on revolutionizing how advanced heart disease is treated. In honor of the occasion, Alexei Marko, CEO & President and Chris Clark, Chief Financial Officer will ring the Closing Bell.
Where:
Nasdaq MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio
When:
Tuesday, January 13, 2015 – 3:45 p.m. to 4:00 p.m. ET
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Tiara™ technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of refractory angina and a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. For more information, visit: www.neovasc.com.
Statements in this press release that are not based on historical or current fact are considered "forward-looking statements" in the context of applicable securities laws. No assurances can be given as to the accuracy of these statements and readers are cautioned not to place undue reliance on such forward-looking statements.
SOURCE Neovasc Inc.
%CIK: 0001399708
For further information: Investor Relations, Neovasc Inc., Chris Clark, 604 248-4138, cclark@neovasc.com
CO: Neovasc Inc.
CNW 07:00e 13-JAN-15
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Neovasc Inc. | |||
(Registrant) | |||
Date: January 13, 2015 | By: | /s/Chris Clark | |
Name: | Chris Clark | ||
Title: | Chief Financial Officer |